Table 2.
Clinical characteristics during treatment with lamivudine-based ART.
| Characteristics | Time Post-ART Initiation | ||||
|---|---|---|---|---|---|
| Baseline | 6 Months | 12 Months | 18 Months | 24 Months | |
| HBV DNA (IU/mL)—occult and chronic | n = 56 (100%) | n = 36 (100%) | n = 34 (100%) | n = 26 (100%) | n = 14 (100%) |
| Undetectable | 5 (8.93) | 16 (44.44) | 17 (50.00) | 14 (53.8) | 10 (71.43) |
| <10 | 6 (10.71) | 8 (22.22) | 6 (17.70) | 4 (15.4) | 1 (7.14) |
| 10 to <2000 | 26 (46.43) | 7 (19.45) | 6 (17.70) | 4 (15.4) | 1 (7.14) |
| ≥ 2000 to <20,000 | 12 (21.43) | 3 (8.33) | 1 (2.90) | 1 (3.9) | 0 |
| ≥ 20,000 to < 2 × 105 | 3 (5.36) | 0 | 1 (2.90) | 1 (3.9) | 0 |
| ≥ 2 × 105 | 4 (7.14) | 2 (5.56) | 3 (8.80) | 2 (7.6) | 2 (14.29) |
| HBV DNA (IU/mL)–occult | n = 25 (100%) | n = 18 (100%) | n = 16 (100%) | n = 13 (100%) | n = 8 (100%) |
| Undetectable | 3 (12) | 9 (50) | 6 (38) | 7 (53.8) | 6 (75) |
| <10 | 4 (16) | 5 (27.7) | 5 (31) | 1 (7.7) | 1 (12.5) |
| 10 to <2000 | 14 (56) | 3 (16.7) | 4 (25) | 4 (30.8) | 0 |
| ≥ 2000 to 20,000 | 2 (8) | 1 (5.6) | 0 | 0 | 0 |
| ≥ 20,000 to <2 × 105 | 0 | 0 | 0 | 0 | 0 |
| ≥ 2 × 105 | 2 (8) | 0 | 1 (6) | 1 (7.7) | 1 (12.5) |
| HBV DNA (IU/mL)—chronic | n = 31(100%) | n = 18 (100%) | n = 18 (100%) | n = 13 (100%) | n = 6 (100%) |
| Undetectable | 2 (6.45) | 7 (38.9) | 11 (61) | 7 (53.9) | 4 (66.6) |
| <10 | 3 (9.7) | 3 (16.7) | 1 (5.6) | 3 (23) | 0 |
| 10 to <2000 | 12 (38.7) | 4 (22.2) | 2 (11.1) | 0 | 1 (16.7) |
| ≥ 2000 to 20,000 | 9 (29.0) | 2 (11.1) | 1 (5.6) | 1 (7.7) | 0 |
| ≥ 20,000 to <2 × 105 | 3 (9.7) | 0 | 1 (5.6) | 1 (7.7) | 0 |
| ≥2 × 105 | 2 (6.45) | 2 (11.1) | 2 (11.1) | 1 (7.7) | 1 (16.7) |
| CD4+ count (cells/mm3) | n = 47(100%) | n = 24(100%) | n = 11(100%) | ||
| <50 | 20 (42.6) | 2 (8.3) | 0 | ||
| 50 to ≤ 350 | 26 (55.3) | 18(75) | 7 (63.6) | ||
| >350 | 1 (2.1) | 4 (16.7) | 4 (36.4) | ||
| Plasma HIV RNA (copies/mL) | n = 41 | n = 22 | n = 19 | ||
| Undetectable (<50) | 0 | 18(81.8) | 19(100) | ||
| <1000 | 2 (4.9) | 3 (13.6) | 0 | ||
| ≥ 1000 | 19 (46.3) | 1 (4.6) | 0 | ||
| >105 | 20 (48.8) | 0 | 0 | ||